Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esberitox
- Development stage
- Unknown
- Lead developer
- Schaper & Bruemmer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Esberitox is an approved herbal medicine (phytotherapeutic) developed and marketed by Schaper & Brümmer. It consists of a proprietary immune-activating complex derived from three main botanical ingredients: *Echinacea* (purple coneflower, specifically *Echinacea purpurea* and *Echinacea pallida*), *Baptisia tinctoria* (wild indigo root), and *Thuja occidentalis* (white cedar). Indicated for the supportive treatment of viral common cold diseases and frequently recurring respiratory tract infections, it functions as an immunomodulator. The mechanism involves enhancing the body's natural defense mechanisms by stimulating the activity of the non-specific immune system, specifically increasing the production and phagocytic activity of macrophages and T-lymphocytes. It has been marketed for over 85 years and holds marketing authorizations in numerous countries, including Germany and China.
- Brand names
- EsberitoxEsberitox COMPACTEsberitox NEsberitox tablets
- Other names
- Echinacea + Baptisia + Thuja
Beyond the preview
Go deeper on Esberitox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esberitox.